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Aims: Assess the impact of radiation doses to neural stem cell (NSC) niches in patients
with IDH-wild-type glioblastoma.
Materials and Methods: Fifty patients were included in the study. NSC niches
[SubVentricular Zone (SVZ) and Sub Granular Zone (SGZ)] were contoured by fusing
CT scans and pre-therapy MRI, Tumor location defined ipsilateral and contralateral SVZ
and SGZ. Prognostic significance of clinical, biological and dosimetric parameters were
examined. We generated a Recursive Partitioning Analysis (RPA) model with independent
prognostic classes.
Results: Median follow-up: 23.8 months. Event free and overall survival (OS): 10 and
19.1 months. Incomplete surgery, PTV (planning target volume), ipsilateral SVZ or NSC
niche mean dose > 57.4Gy, contralateral NSC niche mean dose > 35Gy and bilateral
NSC nichemean dose> 44Gy were significantly correlated with reduced OS. Only EGFR
amplification was an independent prognostic factor (p = 0.019) for OS. RPA generated
independent risk groups: 1 (low risk): [ipsilateral NSC mean dose (INMD) < 58.01Gy and
methylated MGMT promoter], 2: (INMD < 58.01Gy and unmethylated MGMT promoter
and contralateral SVZ mean dose < 18.6Gy; p = 0.43), 3: (INMD < 58.01Gy and
unmethylated MGMT promoter and contralateral SVZ mean dose > 18.6Gy; p = 0.002)
and 4: (very high risk) (INMD > 58.01Gy; p <0.001).
Conclusion: High radiation doses to ipsilateral NSC and contralateral SVZ could have
a negative impact on overall survival in IDH-wild-type glioblastoma population.
Keywords: glioblastoma, MGMT, stem neural niches, radiotherapy, dose, survival impact, neural niches
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INTRODUCTION
Glioblastomas are tumors which currently have a terrible
prognosi Isocitrate Dehydrogenase (IDH)-wild-type
glioblastoma (90%) is most often a primary or de novo tumor on
the contrary to IDH-mutant glioblastoma (10%) which mostly
corresponds to so called “secondary glioblastoma,” resulting from
the progression of a low-grade glioma (according to the new
2016 World Health Organization (WHO) classification)(1). The
Stupp protocol, which consists of radiotherapy and concomitant
chemotherapy with temozolomide has nevertheless succeeded
in increasing the 5-year survival rate from 1.9 to 10.4% (2).
Prognostic factors of patients with glioblastoma are clinical
[age at diagnosis, general state of health and the Karnofsky
Performance Status (KPS)], histomolecular [IDH mutation,
O6-methylguanine-DNA-methyltransferase (MGMT) promoter
methylation status] and therapeutical [extent of surgical
resection] (3).
In 1998, Eriksson et al. reported the existence of neurogenesis
from normal neural stem cells (NSC) in the adult human brain
with a capacity to migrate, and to participate actively in brain
tissue repair (4). These can be found in twomain zones or “neural
niches” in the brain: the Sub Ventricular Zone (SVZ) located
between the lateral ventricles and the striatal parenchyma, and
the Sub Granular Zone (SGZ) confined to the hippocampal
dentate gyrus. Part of these cells, initially found in the neural
niches, could then migrate toward more peripheral zones of
the brain parenchyma leading to more mature cells and the
formation of the tumor mass. Cancer Stem Cells (CSC) deriving
from these NSC could lead to the formation of glioblastoma.
Neural niches therefore harbor both NSC and CSCwhich directly
participate in tumorogenesis (5). The radioresistance of CSC
has been clearly described, (6, 7) especially when they were in
neural niches (8, 9). This radioresistance is reported as one of
the reasons of dramatic prognosis for glioblastoma. However,
different retrospective studies regarding this hypothesis have led
to contradictory results on the prognostic impact of the total
radiation dose to these neural niches (10–12).
Here, we performed a retrospective analysis of patients
irradiated for an IDH-wild-type glioblastoma to investigate the
impact of SGZ and SVZ radiation on progression-free survival
(PFS) and overall survival (OS) in this population of patients. We
employ RPA to divide IDH-wild type glioblastoma patients into
prognostic groups using clinical molecular and dosimetric data.
PATIENTS AND METHODS
Patients
We carried out a single-center retrospective study including all of
the patients newly diagnosed with IDH-wild-type glioblastoma
and treated with radiotherapy and concomitant chemotherapy
according to the Stupp protocol in the University Hospital La
Timone, Marseille, France between January 2008 and January
2013. All patients signed a consent form before inclusion in the
Abbreviations: NSC, neural stem cell; SVZ, SubVentricular Zone; SGZ, Sub
Granular Zone; INMD, ipsilateral NSC mean dose.
study and are included in the SIRIC (Site de Rechcerche Integrée
en Cancérologie) cohort.
For all patients, the anatomopathology diagnosis was
reviewed and immunohistochemistry using anti-IDH1R132H
was performed. If patients were less than 55 years old, we tested
for IDH gene mutations and all of the patients were negative.
Inclusion criteria for the study were:
- age > 18 years old
- proved histological diagnosis of IDH-wild-type glioblastoma
- pre-therapy magnetic resonance (MR) examination available
Patients were excluded for the following reasons: different
radiotherapy protocols (hypofractionated), radiotherapy without
chemotherapy prior to the Stupp protocol and patients without
MR scans.
Delineation and Treatment Planning
Dosimetric data for all of the patients were collected from the
computer base archives. Target volumes were defined according
to European Association of Neuro-Oncology (EANO) guidelines
(GTV, gross target volume; CTV, clinical target volume; PTV,
planning target volume). All of the patients received a total
radiation dose of 60Gy in 30 fractions of 2Gy on PTV. Treatment
plans were drawn up using the Pinnacle planning system.
The SVZ was defined on the CT scan as the lateral wall
of the lateral ventricles with a margin of 5mm. The SGZ was
located in the hippocampus by fusing the images from the CT
scan and the pre-therapy MR scan (Figure 1). Delineation of the
hippocampus was based on Radiation Therapy Oncology Group
(RTOG) guidelines (13).
Tumor location defined the laterality of the studied volumes
(SVZ and SGZ). When the tumor crossed the median line its
geometrical center was used to define laterality. Thus the SVZ
and SGZ were separated into ipsilateral or contralateral volumes.
Furthermore, initial tumor location was divided into 4 groups
according to its proximity to neural niches and to cortex as
initially described by Lim DA et al. (14).
Treatment plans were analyzed for each patient and the
maximum, minimum and average radiation doses were noted
for all of the previously defined volumes. Then a “neural niche”
volume was defined as the sum of the SVZ and SGZ volumes, and
an average dose was calculated for ipsilateral and contralateral
neural niches.
Clinical and Biological Variables and
Follow-Up
The following clinical, dosimetric and biological variables were
assessed for each patient: age at diagnosis, type of surgery,
Mini-Mental State (MMS) and KPS scores, tumor location and
PTV. The following molecular variables were also collected:
methylation status of the MGMT promoter and Epithelial
Growth Factor Receptor (EGFR) amplification (Table 1).
Patient follow-up consisted of a clinical examination once
a week during radiotherapy then again for each round of
chemotherapy, and a MR scan every 2 months. Response and
progression were evaluated according to Response Assessment in
Neuro-Oncology (RANO) criteria (15).
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FIGURE 1 | Example of delineation. (A) Example of hippocampus delineation included SGZ. (B) Example of SVZ delineation from the lateral wall of the lateral
ventricles with a margin of 5mm.
Statistical Analysis
For each given parameter, two groups were defined according to
whether data was below or above the 3rd quartile. All analysis
was carried out with a bilateral alpha risk of 5%. Categorical data
were expressed as frequency or percentage whereas continuous
variables were expressed as median, minimum, and maximum.
The t-test or Mann-Whitney U test was used to compare
quantitative variables. Qualitative variables were analyzed using
the Fisher’s exact or Chi-square tests. Correlations were studied
using Pearson’s or Spearman’s rank correlation. The length of
time until the occurrence of events was estimated using the
Kaplan-Meiermethod and comparedwith a log-rank test. Overall
survival was defined as the length of time between initial surgery
and death from any cause, ending on the date of the last
given information. As for PFS, it was defined as the length of
time between initial surgery and tumor progression or relapse,
ending on the date of the last tumor assessment. Univariate and
multivariate analyses were used according to Cox’s proportional
hazards test in order to estimate the Hazard Ratio (HR). We
treated dosimetric variables as dichotomous variables using the
third quartile as a cut-off. We included in the multivariate
analysis all the variables with p ≤ 0.1 in the univariate analysis.
As a complementary study, RPA was also used to group patients
into different categories. The input variables entered in RPAwere:
Ipsilateral SVZ mean dose, ipsilateral SGZ mean
dose, contralateral SGZ mean dose, contralateral niche
mean dose, ipsilateral niche mean dose, total niche mean
dose, type of surgery, MGMT status, EGFR status, Lim
classification, brain tumor location, GTV, PTV, age, KPS score.
RPA divided patients at each step into two groups based on
the covariate that provided maximum separation with respect
to prognosis and accounted for interactions between factors.
The RPA algorithm is based on the optimized binary partition
of these subgroups which enables classification of patients into
successively more homogeneous prognostic groups based on
multiple input variables. RPART performs a tenfold cross-
classification by default to help evaluate the reliability of the
tree model. The full sample is randomly divided into 10 sub-
samples. Internally, the full RPART tree is carried out with 90%
of the full sample, and the remaining 10% of the sample is used
as a validation dataset to calculate a cross-classification error
rate. This procedure is repeated 10 times, each time with 9
subsets as the modeling dataset and the remaining 1 subset as the
validation dataset. Additional technical details can be found in
this document: (Therneau TM EJ. An Introduction to Recursive
Partitioning Using the RPART Routine. Mayo Clinic, Rochester,
MN. 1997) (16).
In this study, we performed RPA using routinely available
clinical variables and NSC niche dose-volume parameters to
determine risk groups associated with survival. Clinical utility
was enhanced by rounding the cut-off points to the nearest
significant digit. The OS rates were compared between the
RPA risk groups using log-rank tests. The primary endpoint
was survival calculated from the date of surgery to the date
of either the last follow-up or death using the Kaplan-Meier
method. Incomplete or missing data were removed from analysis.
Statistical significance was set at p < 0.05. Analyses were carried
out using the statistics software SPSS version 20 R©.
RESULTS
Among the 67 patients for whom a pre-therapy MR scan
was available, 3 treatment plans could not be recuperated, 6
patients were missing clinical data, 5 patients had mixed tumors
and 3 patients had undergone radiotherapy alone which was
hypofractionated. These patients were all excluded. In total
50 patients were retained for the final analysis. Patients and
dosimetric characteristics are provided in Tables 1, 2. In the
population under study, the mean length of follow-up was
23.8 months (ranges 7.0 to 83.9). Forty-six of the 50 patients
relapsed. In 41 cases, this relapse could be characterized as
ipsilateral (31 patients) or contralateral (10 patients). Median
PFS was estimated at 10 months [IC95 (8.4–11.5)]. Furthermore
41 patients out of 50 had deceased at the time of analysis. The
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TABLE 1 | Patient and tumor characteristics.
Number Percentage
(%)
Mean age 56.2 years
Mean KPS score
<70
>70
unknown
73.27 (50–90)
7
42
1
TYPE OF SURGERY
Total resection
Partial resection
Biospy
35
6
9
70
11
19
MGMT PROMOTER
No methylation
Methylation
Unknown
27
15
8
54
30
16
EGFR
No amplification
Amplification
Unknown
15
16
19
30
32
38
LOCATION
Frontal
Temporal
Parietal
Occipital
17
18
14
1
34
36
28
2
MMS
Normal
Abnormal
Unknown
24
24
2
48
48
4
LIM CLASSIFICATION
Zsv–cortex+ 9 18
Zsv–cortex− 13 26
Zsv+cortex+ 5 10
Zsv+cortex– 17 34
Unknown 6 12
RECURRENCE
No
Local
Regional
Unknown
4
36
6
4
8
72
12
8
median of OS was estimated at 19.1 months [IC95 (14.6–23.7)]
(Figure 2).
Univariate Analysis
Among clinical parameters, only the type of surgery (p = 0.021)
and PTV (p = 0.013) were significantly associated with OS.
Among dosimetric parameters, the mean dose to the ipsilateral
SVZ (p = 0.008), to ipsilateral neural niches (SVZ + SGZ)
(p = 0.004), to the contralateral neural niches (p = 0.016), and
to bilateral neural niches (p= 0.019) were correlated with OS but
had no impact on PFS (Table 3).
Multivariate Analysis
Multivariate analysis revealed only one independent prognostic
factor: EGFR amplification (p = 0.019) with a trend for type of
TABLE 2 | Dosimetric parameters including third quartile (Q3).
Median (cGy) (Min–Max) (cGy) Q3 (Gy)
Ipsilateral SVZ mean dose 5180.95 (2484.60–6067.7) 57.4
Contralateral SVZ mean dose 2662.05 (515.40–5790.60) 40.6
Ipsilateral hippocampus mean dose 5450.05 (400.60–6152.40) 59.04
Contralateral hippocampus mean dose 1755.80 (189.90–5750.00) 33.18
Ipsilateral neural niche mean dose 5314.15 (1721.85–6087.70) 56.97
Contralateral neural niche mean dose 2247.60 (352.65–5591.30) 35.84
Bilateral neural niche mean dose 3711.95 (1072.18–5601.50) 44.06
Median (cc)
PTV 306.61
FIGURE 2 | Overall survival for the entire cohorte.
surgery (p = 0.07) and MGMT promoter methylation status
(p= 0.07) for OS. Again, no factor was associated independently
with PFS (Table 4).
Recursive Partitioning Analysis
We performed RPA to establish a new prognostic model for
OS to identify predictors of survival and generate a clinical
decision tree. As shown in Figure 3, the patients were divided
into four risk groups. Patients with amean ipsilateral neural niche
dose below 58.01Gy and methylated MGMT promoter were
stratified into the low-risk group (group 1) (reference). Patients
with mean ipsilateral neural niche dose below 58.01Gy and
unmethylated MGMT promoter were subdivided according to
mean contralateral SVZ dose into two groups: moderate (group
2) [(mean contralateral SVZ dose < 18.6Gy); p = 0.43] and
high risk (group 3) (mean contralateral SVZ dose > 18.6Gy;
p = 0.002). Patients with mean ipsilateral neural niche doses
above than 58.01Gy were at very high-risk (group 4) in terms
of overall survival (p > 0.001) (Table 5).
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TABLE 3 | Univariate analysis.
p HR 95% CI
Age 0.804 0.996 0.963–1.03
KPS score ≤ 70 0.553 0.728 0.255–2.078
Surgery
Total or partial 0.015 2.294 1.174–4.48
MGMT promoter
methylation (yes)
0.048 0.433 0.189–0.993
EGFR amplification (yes) 0.073 0.484 0.218–1.071
Ipsilateral SVZ mean dose
≥ 57.4 Gy*
0.001 2.418 1.26–4.63
Contralateral SVZ mean
dose ≤ 41.6 Gy*
0.289 0.684 0.339–1.38
Ipsilateral neural niche mean
dose ≤ 57 Gy*
0.004 0.350 0.171–0.714
Contralateral neural niche
mean dose ≥ 35.8 Gy*
0.075 0.436 0.222–0.856
Bilateral neural niche mean
dose ≥ 44 Gy*
0.019 0.434 0.216–0.871
PTV 0.013 1.001–1.005
Location ns
Lim classification ns
*Q3 parameters.
SVZ, SubVentricular Zone; PTV, planning target volume.
TABLE 4 | Multivariate analysis.
p HR 95% CI
Total or partial surgery 0.072 2.691 0.915 7.9
MGMT promoter methylation 0.077 0.391 0.138 1.1
EGFR amplification 0.019 0.356 0.150 0.84
Ipsilateral SVZ mean dose (q3) 0.851 1.193 0.189 7.5
Ipsilateral niche mean dose (q3) 0.142 0.377 0.102 1.3
Contralateral niche mean dose (q3) 0.284 2.003 0.563 7.1
PTV 0.317 1.002 0.998 1
SVZ, SubVentricular Zone; PTV, planning target volume.
DISCUSSION
Despite the multimodality of treatment for glioblastoma,
prognosis still remains very poor and this could partly be
explained by its biomolecular profile and is probably linked to
the involvement of NSC in this disease. Our study reports a
significant negative impact of higher doses of radiation received
by normal stem cells on OS in a homogeneous subgroup of
patients with IDH-wild-type glioblastoma, whilst taking into
account MGMT promoter methylation status (3) and EGFR
amplification. This is the first study about stem cells dose impact
taking into account molecular status in glioblastoma population.
This is also the first study to propose a RPA including molecular
markers and dosimetric parameters to define risk prognostic
groups.
FIGURE 3 | Overall survival curves according RPA subgroups. Group 1 in
blue-group 2 in green-group 3 in yellow-group 4 in purple;
Mean dose homolateral niches < 58Gy + MGMT methylation;
Mean dose homolateral niches <58 Gy+No methylation + Mean dose
contralateral Zsv <18.6Gy;
Mean dose homolateral niches <58 Gy+No methylation + Mean dose
contralateral Zsv >18.6Gy;
Mean dose homolateral niches >58Gy.
Numerous studies have shown that neural niches can promote
tumor development. Following the transformation of NSC into
CSC after a punctual mutation, CSC could migrate out of the
neural niches to initiate tumor growth (5). Furthermore, the
neural niche environment would be ideal for maintaining CSC
in a state of hypoxia, therefore encouraging their radioresistance
(8), but also ideal for nurturing them via the specific growth
factors which can be found around NSC.
Scientific literature reports controversial results. A
retrospective study by Evers et al showed the impact of radiation
therapy on neural niches for 55 patients treated for diffuse grade
III or IV gliomas (10). They reported that a radiation dose >
43Gy to the bilateral SVZ significantly correlated with better
PFS (7.2 vs. 15 months; p = 0.03). In their analysis, a dose >
43Gy to the SVZ appeared to be a positive prognostic factor for
PFS (HR = 0.735; p = 0.019). This study was the first to show
the impact of irradiating neural niches on the survival of patients
with glioblastoma. The authors explained that the lack of impact
on OS was due to the multiple salvage therapies used at relapse
and suggested, in order to defend their results, a sensitivity of
stem cells to low fractionated doses (17).
In 2013 the same team studied a multicentre cohort of
173 patients and reported that radiation doses > 59.4Gy to
the SVZ correlated with better PFS (12.6 vs. 9.9 months;
p = 0.042) confirmed using multivariate analysis (HR = 0.45;
p= 0.009) (11). However, the lack of molecular variables and the
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TABLE 5 | Overall survival according to RPA subgroups and log rank-test.
P-value HR (95.0% CI)
Group 0.000 –
Group 2 vs. 1 0.427 1.591 (0.506– 5.010)
Group 3 vs. 1 0.002 6.340 (1.992–20.178)
Group 4 vs. 1 0.000 13.826 (3.994–47.860)
comparison of two unequal populations (21 patients receiving
the high ipsilateral SVZ dose vs. 152 patients receiving the
lower ipsilateral SVZ dose) again make these results difficult to
interpret. Furthermore, Gupta et al. showed that, for 40 patients
studied, a high radiation dose to the ipsilateral SVZ seemed to
be a positive prognostic factor for OS [HR = 0.87; IC95 (0.77;
0.98)] but without impact on PFS in multivariate analysis (12).
Similar correlations were reported in glioblastoma populations
regarding radiation doses higher than 40 or 50Gy to ipsilateral
neural niches respectively by Chen et al. and Kusumawidjaja et al.
Nevertheless, the fact that all these cohorts were
heterogeneous with grade III and IV diffuse gliomas and/or
that molecular profiles such as MGMT promoter methylation
or IDH1/2 mutations were not taken into consideration, all
represent limits that make the results difficult to interpret and
compare (18, 19).
In our study that focussed on IDH-wild-type glioblastoma,
we found that radiation doses below average to ipsilateral
SVZ (<57.4Gy), to ipsilateral neural niches (<57Gy) and to
contralateral neural niches (<35Gy) had a significant positive
impact on OS with medians (p = 0.001), (p = 0.015), and
(p = 0.029) respectively, but no impact however on PFS. The
coherence of our results is backed by published fundamental
studies.
Neural niches form an ideal environment, perfectly adapted
to CSC survival. Some in vitro and in vivo studies have already
shown that CSC were particularly radioresistant (6, 6, 7, 20),
especially when they were in a hypoxic condition such as that
found in neural niches (9). On the contrary, NSC seem to
have very different characteristics and could even be specifically
sensitive to ionizing radiation (21). Even though these studies
are limited to being done in vitro or in vivo, they highlight a
difference in sensitivity which could help understand the different
results. Thus, when high doses are delivered to neural niches,
perhaps the NSC are eliminated without however destroying
the CSC. Thus, the equilibrium between NSC-CSC would be
disrupted and the neural niche could be recolonized exclusively
by CSC, as has been shown by some mathematical studies (6),
which could explain the decrease observed inOS. Finally, it seems
more than probable that certain subgroups whose tumorogenesis
originates from stem cells would suffer from irradiation of neural
niches.
Several authors have reported also similar clinical results.
Achari et al. reported in a series of 61 glioblastoma patients
that a median dose higher than 55.2Gy to ipsilateral neural
niches was associated with significant lower PFS (0.013) and OS
(p = 0.028). In multivariate analysis, temozolomide compliance,
MGMT promoter methylation status, ipsilateral neural niche
median dose and ipsilateral SVZ median dose were independent
prognostic factors (p < 0.001, 0.011, 0.017, 0.017, respectively)
(22). Elicin et al. reported that a higher dose than 62.25Gy to
ipisilateral neural niches was associated with a poor OS in the
same cohort of patients (23).
In this current study, we used RPA to integrate more
significantly prognostic variables such as molecular and
dosimetric parameters and to avoid subjective selection of
variables. Such an approach has been developed in 2 studies
to stratify glioblastoma patients, one from TCGA and second
from RTOG 0525 datasets with the incorporation of molecular
prognostic markers. In these 2 analyses, MGMT promoter
methylation status and MGMT protein expression participated
in RPA model prediction (24, 25). We identified three significant
prognostic factors: first split with average ipsilateral neural
niche doses below 58Gy, then second split with methylated
MGMT promoter and last split with average ipsilateral SVZ
doses <18.6Gy.
If some other authors have already reported a negative survival
impact of high doses to stem cells, to our knowledge, this is the
first time that dosimetric parameters related to neural niches were
identified as significant prognostic factors by RPA in well-defined
population of de novo glioblastoma.
The limits of our study are the fact that it is a retrospective
study with unknown bias and that our sample number remains
small. On the other hand, our population is homogeneous in
terms of IDH status and treatment modalities and our study
takes into account molecular data associated with survival such
as MGMT promoter methylation status and EGFR amplification.
CONCLUSION
In this study, high radiation doses to neural niches are a
pejorative prognostic factor for patients treated for IDH-wild-
type glioblastoma. Using RPA we identified 4 prognostic groups
of patients according to MGMT promoter methylation status,
maximumdoses delivered to the ipsilateral NSC and contralateral
SVZ. This result contributes to the foundation of knowledge on
stem cells radiation.
These results must be confirmed in a larger series of patients
and then they could be added to dosimetric decision-making in
glioblastoma patients.
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